POC(Point-Of-Care) 혈당 측정 시장 : 제품 유형별, 검사 유형별, 기술별, 휴대성별, 최종 사용자별, 유통 채널별 - 시장 예측(2026-2032년)

The Point-of-Care Glucose Testing Market was valued at USD 7.65 billion in 2025 and is projected to grow to USD 8.14 billion in 2026, with a CAGR of 7.98%, reaching USD 13.10 billion by 2032.

An authoritative orientation to how converging technologies, digital systems, and patient-centric delivery are reshaping point-of-care glucose testing and care pathways

Point-of-care glucose testing occupies a central role in contemporary diabetes care pathways, where speed, accuracy, and accessibility determine clinical outcomes and patient quality of life. Over the past decade clinical practice and consumer expectations have pushed diagnostics from episodic laboratory tests toward continuous, near-patient monitoring that supports real-time therapeutic decisions and remote care models. This evolution has been driven by advances across multiple domains: sensor chemistry and photonics that improve signal fidelity, miniaturized electronics and connectivity that enable persistent data flows, and interoperable software applications that translate streams of glucose readings into clinically actionable insights.

Consequently, stakeholders across the ecosystem are recalibrating priorities. Device manufacturers are balancing investments between traditional glucose meters and test strips, while expanding portfolios to include continuous glucose monitoring devices and complementary sensors. Health systems and payers are evaluating the clinical and operational trade-offs of ambulatory surgical centers versus hospital-based laboratories, and the rise of assisted and self-monitoring paradigms at home is reshaping distribution choices. In parallel, a growing emphasis on non-invasive and minimally invasive test types, coupled with distinct technology approaches such as colorimetric, electrochemical, and photometric methods, is broadening the pathways through which innovation can reach clinicians and consumers.

As a result, point-of-care glucose testing is no longer solely a laboratory concern but a strategic domain that intersects with digital health, retail distribution, and care delivery redesign. This report synthesizes those intersections so clinical leaders, R&D teams, and commercial strategists can navigate the complex landscape with clarity and make decisions that align product development, channel strategy, and regulatory engagement for maximal clinical and economic impact.

How real-time monitoring, hybrid distribution models, sensor innovation, and integrated software platforms are collectively transforming competitive and clinical dynamics in glucose testing

The landscape of point-of-care glucose testing is undergoing transformative shifts that are redefining competitive boundaries, clinical workflows, and patient expectations. Real-time continuous glucose monitoring has moved from a specialized tool into mainstream clinical practice, enabling proactive glycemic control and remote patient management. This has catalyzed investment in sensor diversity, where enzymatic sensors remain foundational for many applications while emerging optical approaches aim to reduce invasiveness and improve user comfort. At the same time, software applications have matured from passive logging tools into integrated platforms that enable decision support, telemetry to care teams, and algorithm-driven alerts that reduce acute events.

Concurrently, distribution dynamics are shifting toward hybrid models that blend direct sales, hospital and retail pharmacy networks, and increasingly sophisticated online pharmacy channels that include manufacturer storefronts and third-party marketplaces. The rise of home-based monitoring, both self-managed and assisted, is prompting manufacturers to prioritize portability and user-centric design, while benchtop platforms continue to serve diagnostic laboratories and large hospital installations. Diagnostic laboratories themselves are segmented into hospital-based and independent facilities, creating differentiated procurement cycles and clinical integration challenges. These shifts are compounded by regulatory and reimbursement changes that are encouraging cross-sector partnerships between device companies, health systems, and digital health vendors.

Taken together, these transformative movements demand a strategic response that combines product differentiation, distribution innovation, and clinical evidence generation. Industry participants who align sensor technology choices-whether electrochemical, photometric, or colorimetric-with targeted end-user workflows, and who build interoperable software layers to support clinician and patient decision-making, will be better positioned to capture clinical adoption and scale sustainably.

Implications of 2025 United States trade policy adjustments on sourcing, manufacturing footprints, distribution economics, and strategic supplier risk management in glucose testing

The introduction of tariffs and trade policy adjustments in the United States during 2025 has had immediate and cascading implications across manufacturing choices, procurement strategies, and global supply chain design for devices and consumables used in point-of-care glucose testing. Components such as semiconductor chips, specialized optics, and chemical reagents can traverse multiple international supply chains, and tariff shifts alter the relative economics of sourcing locations, incentivizing companies to reassess contract manufacturing, localization of production, and inventory strategies. Consequently, procurement teams have reprioritized supplier qualification criteria to include trade exposure and logistics resilience alongside traditional quality and cost metrics.

In practical terms, companies have responded by diversifying supplier bases and exploring regional manufacturing footprints that can mitigate tariff exposure while preserving access to critical components. For products with thinner margins, such as test strips, tariff-driven cost pressure is particularly acute and has accelerated negotiations with distribution partners to re-evaluate pricing frameworks and payment terms. Software-centric offerings and cloud-based services have experienced a different dynamic; with lower physical component dependence, these solutions have become strategic differentiators that can offset hardware cost pressures by delivering added value through analytics, adherence programs, and remote monitoring services.

Moreover, the policy environment has nudged industry participants to improve transparency in their supply chains and to engage more proactively with payers and procurement bodies to align reimbursement pathways with evolving cost structures. While tariffs alone do not determine long-term competitive outcomes, they have sharpened focus on operational agility, supplier risk management, and strategic partnerships, and they have accelerated a shift toward business models that emphasize recurring revenue through software and service offerings as a hedge against hardware-related cost volatility.

Strategic segmentation analysis revealing how product architectures, end-user workflows, distribution pathways, assay modalities, and portability choices shape adoption and design priorities

A segmentation-driven lens reveals nuanced opportunities and operational challenges across product, end user, distribution, test type, technology, and portability dimensions. In product type, continuous glucose monitoring devices, which encompass both intermittently scanned and real-time systems, are redefining expectations around monitoring frequency and clinician workflows, while traditional glucose meters and test strips remain vital for point checks and settings where continuous monitoring is less practical. Sensors present a bifurcation between enzymatic approaches with well-established analytical performance and newer optical sensors that aim to achieve lower invasiveness and improved user acceptance; software applications increasingly serve as the integrative layer that translates raw readings into management pathways.

With respect to end users, ambulatory surgical centers demand rapid, reliable point-of-care results integrated into perioperative decision-making, whereas diagnostic laboratories-both hospital-based and independent-require standardized workflows and connectivity for lab information systems. Home care has bifurcated into assisted home care and self-monitoring populations, each with distinct usability and support needs, and hospitals and clinics, spanning large hospital systems to small clinics, have contrasting procurement cycles and clinical integration requirements. Distribution channels vary from direct sales models that support clinical account management to hospital pharmacies and retail pharmacies that prioritize supply continuity, while online pharmacies, whether manufacturer-operated storefronts or third-party marketplaces, are increasingly important for direct-to-consumer access.

Test types, categorized into invasive, minimally invasive, and non-invasive methodologies, create specific regulatory and clinical evidence demands that shape development timelines and adoption curves. Technology choices-colorimetric, electrochemical, and photometric-bring different performance, cost, and manufacturability trade-offs that must be matched to intended use cases. Portability considerations, whether benchtop or portable, further influence product design and target audiences. In synthesis, the most successful product strategies will be those that align sensor chemistry and assay format with targeted end-user workflows and distribution pathways, supported by software features that reduce friction and enhance clinical utility.

How regional regulatory regimes, payer dynamics, manufacturing footprints, and channel preferences across the Americas, Europe Middle East & Africa, and Asia-Pacific determine adoption pathways

Regional dynamics play a decisive role in shaping clinical adoption, regulatory strategies, and supply chain choices across the point-of-care glucose testing ecosystem. In the Americas, care delivery is characterized by a strong emphasis on outpatient and home-based monitoring, rapid adoption of continuous glucose monitoring technologies, and a commercial environment where payer negotiation and value demonstration are critical for scale. Regulatory processes and reimbursement mechanisms vary between national and subnational payers, necessitating tailored evidence generation and pricing strategies that resonate with both public and private purchasers.

Within Europe, Middle East & Africa, regulatory harmonization efforts and diversified healthcare infrastructure create both opportunities and complexity. Western European markets often exhibit high standards for clinical evidence and interoperability, while parts of the Middle East and Africa emphasize affordability and supply chain robustness, encouraging partnerships that localize assembly or distribution. In contrast, Asia-Pacific is highly heterogeneous with pockets of rapid technological uptake, substantial domestic manufacturing capacity, and varying regulatory regimes; in some economies, local manufacturers are significant players and procurement is influenced by national industrial policies. Across all regions, online pharmacy penetration, direct-to-consumer channels, and retail pharmacy networks influence how devices and consumables reach patients, and regional differences in clinical practice guidelines shape the prioritization of continuous versus episodic monitoring.

Therefore, companies seeking international expansion must design regulatory, commercial, and supply chain strategies that reflect regional idiosyncrasies. This requires investing in localized evidence generation, building distribution relationships that align with hospital and pharmacy procurement models, and, where appropriate, establishing regional manufacturing or assembly capabilities to reduce lead times and mitigate tariff exposure.

How differentiated portfolios, digital ecosystem integration, channel strategies, and supply chain resilience are shaping competitive advantage among leading glucose testing companies

Competitive dynamics among leading companies are increasingly shaped by portfolio breadth, integration of digital ecosystems, and the ability to deliver clinical outcomes across diverse care settings. Market-leading device manufacturers have focused on extending continuous glucose monitoring capabilities while maintaining presence in glucose meters and test strip segments to serve a wide range of clinical scenarios. Strategic partnerships with software developers and telehealth providers have enabled device vendors to offer care management services that improve adherence, support remote titration of therapies, and generate real-world evidence that strengthens reimbursement cases.

At the same time, smaller and niche players are targeting differentiated sensor technologies, including optical and novel minimally invasive approaches, to capture specialist use cases and to create acquisition targets for larger firms seeking technological acceleration. Distribution strategies vary; some companies emphasize direct sales and hospital pharmacy relationships to secure institutional adoption, while others pursue omnichannel commercialization that leverages retail pharmacy networks and online marketplaces for consumer reach. Supply chain resilience, including dual sourcing and regional manufacturing, has become a strategic priority, and companies that combine robust quality systems with flexible manufacturing arrangements are better positioned to manage component volatility. Overall, firms that can integrate hardware, software, services, and channel execution into a coherent proposition will have an advantage in convincing clinicians, payers, and patients of the sustained value of their offerings.

Actionable strategic priorities for device makers and commercial teams to accelerate adoption, diversify risk, and align product innovation with payer and clinical needs

Industry leaders should adopt a multi-dimensional strategy that prioritizes technological diversification, channel innovation, and operational resilience to capture growth and mitigate risk. First, invest selectively in advancing sensor technologies that reduce invasiveness and improve user experience while preserving analytical robustness, and concurrently develop modular architectures that allow rapid integration of new sensor chemistries or optical components. Second, expand digital capabilities by building interoperable software platforms that deliver clinician decision support, patient engagement tools, and adherence programs, thereby creating recurring revenue streams that offset hardware margin pressures.

Additionally, diversify manufacturing and supplier footprints to reduce exposure to trade-policy shocks and logistics disruptions, and consider regional manufacturing or assembly to shorten lead times for critical consumables. Strengthen partnerships with hospitals, diagnostic laboratories-both hospital-based and independent-and pharmacy networks, including manufacturer-operated online channels and third-party marketplaces, to create a balanced distribution mix that reaches patients across ambulatory surgical centers, home care settings, and clinics of varying sizes. Finally, engage early with regulators and payers to design evidence-generation programs that demonstrate clinical utility and cost-effectiveness across invasive, minimally invasive, and non-invasive test modalities, and incorporate scenario planning into commercial forecasts to ensure agility in the face of policy or reimbursement shifts.

A rigorous mixed-methods research framework combining stakeholder interviews, regulatory and patent analysis, clinical literature review, and supply chain scenario testing to validate actionable insights

The analysis underpinning this report synthesizes primary qualitative insights with comprehensive secondary evidence to build a robust understanding of clinical, commercial, and technological dynamics. Primary research included structured interviews with clinicians, procurement leaders, diagnostic laboratory managers, home care providers, pharmacy chain strategists, and manufacturing executives to capture frontline perspectives on device performance, workflow integration, and distribution preferences. These insights were triangulated with regulatory filings, peer-reviewed clinical studies, device approval summaries, patent landscape reviews, and technology feasibility assessments to validate technical claims and adoption drivers.

Methodologically, the study applies a segmentation framework across product types, end users, distribution channels, test types, technologies, and portability to ensure findings are actionable for discrete commercial strategies. Supply chain and tariff sensitivity analyses were conducted using supplier mapping and scenario-based impact assessments to highlight operational vulnerabilities and mitigation options. Finally, the research was subjected to internal validation workshops with domain experts to prioritize strategic implications and to ensure the recommendations are aligned with clinical practice realities and commercial operational constraints.

A concise synthesis of how technological advances, distribution evolution, and supply chain resilience combine to create strategic imperatives for diabetes care stakeholders

Point-of-care glucose testing is at an inflection point where technological innovation, evolving care delivery models, and shifting commercial dynamics converge to create both opportunity and complexity. Continuous monitoring technologies, advances in sensor chemistry and optics, and more capable software ecosystems are enabling a shift from episodic measurement to continuous, integrated care management. At the same time, distribution evolution-spanning direct sales, hospital and retail pharmacies, and online marketplaces-and policy dynamics such as tariff adjustments require commercial leaders to build agility into their sourcing, pricing, and channel strategies.

Ultimately, success in this environment will favor organizations that can align product design with targeted end-user workflows, leverage software and services to amplify clinical value, and construct resilient supply chains that mitigate trade and logistics risk. By combining precise segmentation, regionally informed strategies, and disciplined evidence generation, stakeholders can convert the current period of change into a sustained competitive advantage and improved outcomes for patients living with diabetes.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Definition
• 1.3. Market Segmentation & Coverage
• 1.4. Years Considered for the Study
• 1.5. Currency Considered for the Study
• 1.6. Language Considered for the Study
• 1.7. Key Stakeholders

2. Research Methodology

• 2.1. Introduction
• 2.2. Research Design
  • 2.2.1. Primary Research
  • 2.2.2. Secondary Research
• 2.3. Research Framework
  • 2.3.1. Qualitative Analysis
  • 2.3.2. Quantitative Analysis
• 2.4. Market Size Estimation
  • 2.4.1. Top-Down Approach
  • 2.4.2. Bottom-Up Approach
• 2.5. Data Triangulation
• 2.6. Research Outcomes
• 2.7. Research Assumptions
• 2.8. Research Limitations

3. Executive Summary

• 3.1. Introduction
• 3.2. CXO Perspective
• 3.3. Market Size & Growth Trends
• 3.4. Market Share Analysis, 2025
• 3.5. FPNV Positioning Matrix, 2025
• 3.6. New Revenue Opportunities
• 3.7. Next-Generation Business Models
• 3.8. Industry Roadmap

4. Market Overview

• 4.1. Introduction
• 4.2. Industry Ecosystem & Value Chain Analysis
  • 4.2.1. Supply-Side Analysis
  • 4.2.2. Demand-Side Analysis
  • 4.2.3. Stakeholder Analysis
• 4.3. Porter's Five Forces Analysis
• 4.4. PESTLE Analysis
• 4.5. Market Outlook
  • 4.5.1. Near-Term Market Outlook (0-2 Years)
  • 4.5.2. Medium-Term Market Outlook (3-5 Years)
  • 4.5.3. Long-Term Market Outlook (5-10 Years)
• 4.6. Go-to-Market Strategy

5. Market Insights

• 5.1. Consumer Insights & End-User Perspective
• 5.2. Consumer Experience Benchmarking
• 5.3. Opportunity Mapping
• 5.4. Distribution Channel Analysis
• 5.5. Pricing Trend Analysis
• 5.6. Regulatory Compliance & Standards Framework
• 5.7. ESG & Sustainability Analysis
• 5.8. Disruption & Risk Scenarios
• 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Point-of-Care Glucose Testing Market, by Product Type

• 8.1. Continuous Glucose Monitoring Devices
  • 8.1.1. Intermittently Scanned
  • 8.1.2. Real Time
• 8.2. Glucose Meters
• 8.3. Sensors
  • 8.3.1. Enzymatic
  • 8.3.2. Optical
• 8.4. Software Apps
• 8.5. Test Strips

9. Point-of-Care Glucose Testing Market, by Test Type

• 9.1. Invasive
• 9.2. Minimally Invasive
• 9.3. Non Invasive

10. Point-of-Care Glucose Testing Market, by Technology

• 10.1. Colorimetric
• 10.2. Electrochemical
• 10.3. Photometric

11. Point-of-Care Glucose Testing Market, by Portability

• 11.1. Benchtop
• 11.2. Portable

12. Point-of-Care Glucose Testing Market, by End User

• 12.1. Ambulatory Surgical Centers
• 12.2. Diagnostic Laboratories
  • 12.2.1. Hospital Based Labs
  • 12.2.2. Independent Labs
• 12.3. Home Care
  • 12.3.1. Assisted Home Care
  • 12.3.2. Self Monitoring
• 12.4. Hospitals & Clinics
  • 12.4.1. Large Hospitals
  • 12.4.2. Small Clinics

13. Point-of-Care Glucose Testing Market, by Distribution Channel

• 13.1. Direct Sales
• 13.2. Hospital Pharmacies
• 13.3. Online Pharmacies
  • 13.3.1. Manufacturer Websites
  • 13.3.2. Third Party Marketplaces
• 13.4. Retail Pharmacies

14. Point-of-Care Glucose Testing Market, by Region

• 14.1. Americas
  • 14.1.1. North America
  • 14.1.2. Latin America
• 14.2. Europe, Middle East & Africa
  • 14.2.1. Europe
  • 14.2.2. Middle East
  • 14.2.3. Africa
• 14.3. Asia-Pacific

15. Point-of-Care Glucose Testing Market, by Group

• 15.1. ASEAN
• 15.2. GCC
• 15.3. European Union
• 15.4. BRICS
• 15.5. G7
• 15.6. NATO

16. Point-of-Care Glucose Testing Market, by Country

• 16.1. United States
• 16.2. Canada
• 16.3. Mexico
• 16.4. Brazil
• 16.5. United Kingdom
• 16.6. Germany
• 16.7. France
• 16.8. Russia
• 16.9. Italy
• 16.10. Spain
• 16.11. China
• 16.12. India
• 16.13. Japan
• 16.14. Australia
• 16.15. South Korea

17. United States Point-of-Care Glucose Testing Market

18. China Point-of-Care Glucose Testing Market

19. Competitive Landscape

• 19.1. Market Concentration Analysis, 2025
  • 19.1.1. Concentration Ratio (CR)
  • 19.1.2. Herfindahl Hirschman Index (HHI)
• 19.2. Recent Developments & Impact Analysis, 2025
• 19.3. Product Portfolio Analysis, 2025
• 19.4. Benchmarking Analysis, 2025
• 19.5. Abbott Laboratories
• 19.6. AgaMatrix, Inc.
• 19.7. Ascensia Diabetes Care Holdings AG
• 19.8. B. Braun Melsungen AG
• 19.9. Bayer AG
• 19.10. Becton, Dickinson and Company
• 19.11. Dexcom, Inc.
• 19.12. EKF Diagnostics Holdings plc
• 19.13. F. Hoffmann-La Roche Ltd
• 19.14. GlySens, Inc.
• 19.15. HemoCue AB (Radiometer Group)
• 19.16. i-Health Labs, Inc.
• 19.17. i-SENS, Inc.
• 19.18. Johnson & Johnson
• 19.19. Medtronic plc
• 19.20. Nipro Corporation
• 19.21. Nova Biomedical Corporation
• 19.22. Sinocare Inc.
• 19.23. Trividia Health, Inc.